Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 19.11.2024
Formycon AG
Press Release // November 19, 2024
Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, „Formycon“) invites to the conference call and webcast for the publication of the nine-month results 2024 on November 28, 2024. [ … ]
Mon, 18.11.2024
Formycon AG
Press Release // November 18, 2024
Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of FYB203 for the treatment of Neovascular Age-Related [ … ]
Fri, 15.11.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Planegg-Martinsried, Germany, November 15, 2024 – Formycon (FSE: FYB, "Formycon“) announces that the European Medicines Agency (EMA) published today that the Co [ … ]
Mon, 11.11.2024
Formycon AG
Press Release // November 11, 2024Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
Dr. Stefan Glombitza has been appointed as CEO for three more years and will lead Formycon through the next phase of the company's development
Formycon shares will be admitt [ … ]
Mon, 04.11.2024
Formycon AG
Press Release // November 04, 2024
Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
Application for admission to trading on the regulated market (Prime Standard) of the Frankfurt Stock Exchange will be submitted today
Trading of Formycon shares on the Prime Standard segment is expected to start on November 12, [ … ]
Wed, 16.10.2024
Formycon AG
Press Release // October 16, 2024
Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
The comparative analytical evaluation results indicate that the proposed Keytruda®-biosimilar FYB206 is structurally and functionally highly similar to the reference [ … ]
Tue, 01.10.2024
Formycon AG
Company Name:
Formycon AG
ISIN:
DE000A1EWVY8
Reason for the research:
FYB202 approval in EU and US
Recommendation:
Buy
from:
01.10.2024
Target price:
€82
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000 [ … ]
Mon, 30.09.2024
Formycon AG
Press Release // September 30, 2024
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
OtulfiTMreceived FDA approval for both subcutaneous and intravenous formulations, to treat the same conditions as Stelara®
Approval represents the third successful FDA approval for a Formycon biosimilar, two of them in [ … ]
Fri, 27.09.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Planegg-Martinsried, Germany, September 27, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the U.S. Food and Drug Administration (“FDA”) today approved FYB202/OtulfiTM [ … ]
Fri, 27.09.2024
Formycon AG
Press Release // September 27, 2024Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
FYB202/Otulfi® received European Commission (EC) approval for both subcutaneous and intravenous formulations, providing a high-quality treatment option for European [ … ]